Posted On: 07/11/2016 3:18:42 PM
Post# of 72447
Brilacidin's short half-life is another advantage over Oritavancin.
"In fact, over the past year or so, the FDA has approved three new ABSSSI compounds from existing classes of antibiotics: dalbavancin (lipoglycopeptide); tedizolid (oxazolidinone); and oritavancin (lipoglycopeptide). Two of these have very long half-lives. This raises the concern that bacteria have prolonged exposure to subtherapeutic levels, a risk factor for the development of resistance. In addition, it is difficult to discontinue a long half-life drug should adverse events occur."
http://cellceutix.com/cellceutix-announces-fi...cpkna.dpuf
"Candidly, we do not view oritavancin as a potential competitor to our Brilacidin because of several key differentiators, namely pharmacokinetic profiles and subsequent implications. Ortavancin is a lipoglycopeptide, the same class of drug as Durata Pharmaceutical’s Dalvance® (Dalbavancin), and both drugs have a very long half-life of approximately one to two weeks. This means that the drug remains in a patient’s system for a considerable period following dosing, which has the potential for contraindication with other medicines and questions concerning metabolism and drug resistance. Brilacidin, a new class of drug, has a half-life of only 13 to 16 hours, a time frame that we believe is ideal for a one-time treatment, while greatly decreasing the chance of resistance developing."
http://cellceutix.com/cellceutix-prepares-for...0DxJx.dpuf
"In fact, over the past year or so, the FDA has approved three new ABSSSI compounds from existing classes of antibiotics: dalbavancin (lipoglycopeptide); tedizolid (oxazolidinone); and oritavancin (lipoglycopeptide). Two of these have very long half-lives. This raises the concern that bacteria have prolonged exposure to subtherapeutic levels, a risk factor for the development of resistance. In addition, it is difficult to discontinue a long half-life drug should adverse events occur."
http://cellceutix.com/cellceutix-announces-fi...cpkna.dpuf
"Candidly, we do not view oritavancin as a potential competitor to our Brilacidin because of several key differentiators, namely pharmacokinetic profiles and subsequent implications. Ortavancin is a lipoglycopeptide, the same class of drug as Durata Pharmaceutical’s Dalvance® (Dalbavancin), and both drugs have a very long half-life of approximately one to two weeks. This means that the drug remains in a patient’s system for a considerable period following dosing, which has the potential for contraindication with other medicines and questions concerning metabolism and drug resistance. Brilacidin, a new class of drug, has a half-life of only 13 to 16 hours, a time frame that we believe is ideal for a one-time treatment, while greatly decreasing the chance of resistance developing."
http://cellceutix.com/cellceutix-prepares-for...0DxJx.dpuf
Quote:
whereas Brilacidin is a totally new class of antibiotics which, by its mechanism, is unlikely to allow bacteria to survive to develop resistance.
(0)
(0)
